VTVT
vTv Therapeutics Inc is a biopharmaceutical company engaged in drug discovery and development. Its therapies are intended to treat diseases such as Alzheimer\'s and type-II diabetes. Its other products include TTP399, type II diabetes drug candidate.
vTv Therapeutics Inc. (VTVT) is rated C (2.2/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Profitability (B-); its weakest is Growth (F). The rating has held at C for 5 weeks.
Quantitative Factor Evaluation • Updated
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-11-15 | B- (3.0) | F (0.1) | B- (3.1) | C- (2.0) | C+ (2.6) | C (2.2) |
| 2026-11-08 | B- (3.0) | D- (1.0) | B- (3.1) | C (2.4) | C+ (2.6) | C (2.4) |
| 2026-11-01 | B- (3.0) | F (0.2) | B- (3.1) | C+ (2.8) | C+ (2.7) | C (2.4) |
| 2026-10-25 | B- (3.0) | F (0.2) | B (3.2) | C+ (2.5) | C+ (2.6) | C (2.3) |
| 2026-10-18 | B- (3.0) | F (0.1) | B (3.2) | C (2.3) | C+ (2.6) | C (2.3) |